Shopping Cart 0
Cart Subtotal
USD 0

Intas Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and markets pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitryptyline, erythropoietin, filgrastim, follicle stimulating hormone (FSH), rituximab, ampicillin, albendazole, benezepril, and caprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma derived product based therapies. It has nine formulation manufacturing facilities and two active pharmaceutical ingredient (API) and intermediate facilities in India. The company markets its products globally through internal sales force and a network of distributors. Intas is headquartered in Ahmedabad, Gujarat, India.

Intas Pharmaceuticals Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Intas Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Teva Pharma May Sell European Oncology and Pain Assets 13

Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 15

Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 16

Intas Pharma to Acquire Gujarat-based Biotechnology Unit of RPG Life Sciences for USD3.7 Million 18

Intas Pharma Acquires Hospital Business of Combino Pharm 19

Private Equity 20

Capital International Acquires 3% Stake in Intas Pharma from ChrysCapital for USD106 Million 20

Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 21

ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For USD 56.1 Million 22

ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For USD 56 Million 23

Partnerships 24

Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 24

Licensing Agreements 25

Accord Healthcare Enters into Licensing Agreement with Shanghai Henlius Biotech 25

Intas Pharma Enters into Licensing Agreement with Iconovo 26

Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 27

Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 28

Equity Offering 29

Intas Pharma Files Registration Statement For IPO To Raise Up To USD 200 Million 29

Acquisition 30

Accord Healthcare Acquires Essential Pharma 30

Actavis Acquires Auden Mckenzie for USD458 Million 31

Intas Pharmaceuticals Ltd-Key Competitors 32

Intas Pharmaceuticals Ltd-Key Employees 33

Intas Pharmaceuticals Ltd-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Intas Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intas Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Intas Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Teva Pharma May Sell European Oncology and Pain Assets 13

Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 15

Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 16

Intas Pharma to Acquire Gujarat-based Biotechnology Unit of RPG Life Sciences for USD3.7 Million 18

Intas Pharma Acquires Hospital Business of Combino Pharm 19

Capital International Acquires 3% Stake in Intas Pharma from ChrysCapital for USD106 Million 20

Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 21

ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For USD 56.1 Million 22

ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For USD 56 Million 23

Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 24

Accord Healthcare Enters into Licensing Agreement with Shanghai Henlius Biotech 25

Intas Pharma Enters into Licensing Agreement with Iconovo 26

Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 27

Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 28

Intas Pharma Files Registration Statement For IPO To Raise Up To USD 200 Million 29

Accord Healthcare Acquires Essential Pharma 30

Actavis Acquires Auden Mckenzie for USD458 Million 31

Intas Pharmaceuticals Ltd, Key Competitors 32

Intas Pharmaceuticals Ltd, Key Employees 33

Intas Pharmaceuticals Ltd, Other Locations 34

Intas Pharmaceuticals Ltd, Subsidiaries 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and markets pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitryptyline, erythropoietin, filgrastim, follicle stimulating hormone (FSH), rituximab, ampicillin, albendazole, benezepril, and caprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma derived product based therapies. It has nine formulation manufacturing facilities and two active pharmaceutical ingredient (API) and intermediate facilities in India. The company markets its products globally through internal sales force and a network of distributors. Intas is headquartered in Ahmedabad, Gujarat, India.

Intas Pharmaceuticals Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Intas Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Teva Pharma May Sell European Oncology and Pain Assets 13

Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 15

Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 16

Intas Pharma to Acquire Gujarat-based Biotechnology Unit of RPG Life Sciences for USD3.7 Million 18

Intas Pharma Acquires Hospital Business of Combino Pharm 19

Private Equity 20

Capital International Acquires 3% Stake in Intas Pharma from ChrysCapital for USD106 Million 20

Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 21

ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For USD 56.1 Million 22

ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For USD 56 Million 23

Partnerships 24

Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 24

Licensing Agreements 25

Accord Healthcare Enters into Licensing Agreement with Shanghai Henlius Biotech 25

Intas Pharma Enters into Licensing Agreement with Iconovo 26

Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 27

Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 28

Equity Offering 29

Intas Pharma Files Registration Statement For IPO To Raise Up To USD 200 Million 29

Acquisition 30

Accord Healthcare Acquires Essential Pharma 30

Actavis Acquires Auden Mckenzie for USD458 Million 31

Intas Pharmaceuticals Ltd-Key Competitors 32

Intas Pharmaceuticals Ltd-Key Employees 33

Intas Pharmaceuticals Ltd-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Intas Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Intas Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Intas Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Teva Pharma May Sell European Oncology and Pain Assets 13

Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 15

Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 16

Intas Pharma to Acquire Gujarat-based Biotechnology Unit of RPG Life Sciences for USD3.7 Million 18

Intas Pharma Acquires Hospital Business of Combino Pharm 19

Capital International Acquires 3% Stake in Intas Pharma from ChrysCapital for USD106 Million 20

Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 21

ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For USD 56.1 Million 22

ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For USD 56 Million 23

Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 24

Accord Healthcare Enters into Licensing Agreement with Shanghai Henlius Biotech 25

Intas Pharma Enters into Licensing Agreement with Iconovo 26

Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 27

Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 28

Intas Pharma Files Registration Statement For IPO To Raise Up To USD 200 Million 29

Accord Healthcare Acquires Essential Pharma 30

Actavis Acquires Auden Mckenzie for USD458 Million 31

Intas Pharmaceuticals Ltd, Key Competitors 32

Intas Pharmaceuticals Ltd, Key Employees 33

Intas Pharmaceuticals Ltd, Other Locations 34

Intas Pharmaceuticals Ltd, Subsidiaries 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS